Upgrading the company’s domestic generic business “as a core” is among targets outlined by Japan’s Towa Pharmaceutical in a new three-year business plan stretching to April 2024, although the firm recognizes it must “secure stable supply and provide appropriate information based on thorough manufacturing control and quality control to regain trust in generics.”
With generic penetration in Japan reaching 79.4% at the end of 2020, narrowly outside the government target of 80% by...




